Comparative Pharmacology
Head-to-head clinical analysis: CORTRIL versus ORASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTRIL versus ORASONE.
CORTRIL vs ORASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
None Documented
None Documented
Clinical Note
moderateDiflorasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin."
Clinical Note
moderateDiflorasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin."
Clinical Note
moderateDiflorasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin."
Clinical Note
moderateDiflorasone + Trovafloxacin
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Trovafloxacin."